一、受教育及工作经历 Education and Work Experience
1990年–1995年,山东农业大学,畜牧兽医专业,学士学位
1995年–1998年,山东农业大学,动物繁殖学,硕士学位
1998年–2002年,山东泰山医学院,基础医学部,讲师
2002年–2006年,上海交通大学医学院,人体解剖与组织胚胎学,博士学位
2006年–2008年,中国农业科学院北京畜牧兽医研究所,博士后
2008年–2009年,德国 Ludwig Maximilian University of Munich,博士后
2010年–2018年,上海交通大学医学院,实验动物科学部,副研究员
2018年–至今,昆明理工大学灵长类转化医学研究院,教授
1990-1995, Shandong Agricultural University, Bachelor of Animal Husbandry and Veterinary Medicine.
1995-1998, Shandong Agricultural University, Master of Animal Breeding.
1998-2002, Lecturer,Department of Basic Medicine, Shandong Taishan Medical College.
2002-2006, Shanghai Jiaotong University School of Medicine, Human Anatomy and Histology, Ph.D.
2006-2008,Postdoctoral Fellow, Beijing Institute of Animal Science and Veterinary Medicine, Chinese Academy of Agricultural Sciences.
2008-2009,Postdoctoral Fellow,Ludwig Maximilian University of Munich, Germany.
2010–2018,Associate Professor,Department of Laboratory Animal Science, School of Medicine, Shanghai Jiaotong University.
2018–present, Professor,Institute of Primate Translational Medicine,Kunming University of Science and Technology.
二、主要研究方向 Main Research Directions
1.灵长类动物克隆技术的研究
2.克隆技术在人类疾病模型构建中的应用
3.遗传性疾病的基因治疗
1. Research on cloning technology of primates.
2. The application of cloning technology in the construction of human disease model.
3. Gene therapy for hereditary diseases.
三、科研领域描述 Description of Scientific Research
克隆技术的核心是利用MII期卵母细胞将成体细胞经过重新编程,恢复分化全能性并重新发育成个体。基于克隆技术平台进行体细胞重编程关键因素的研究,从而提高对灵长类早期胚胎发育过程的认知,促进克隆技术的发展,利用克隆技术制作遗传背景一致的基因修饰的非人灵长类疾病模型。Cas9技术的发展极大提高了在胚胎期和成体细胞中基因进行基因编辑的可能性,探索基于rAAV介导的基因重组和单碱基基因编辑技术治疗人类遗传病的方法,促进遗传病治疗方法的临床转化。
The core of cloning technology is the use of MII stage oocytes to reprogram adult cells to restore differentiation pluripotency and re-develop into individuals. Based on the cloning technology platform, the key factors of somatic reprogramming are studied to improve the understanding of the early embryonic development process of primates, promote the development of cloning technology, and use the cloning technology to produce genetically modified non-human primate disease modelwith consistent genetic background. The development of Cas9 technology has greatly improved the possibility of gene editing in embryonic and adult cells, exploring methods based on rAAV-mediated gene recombination and single-base gene editing technology for the treatment of human genetic diseases, and promoting the treatment of genetic diseases forclinical transformation.
四、承担科研项目情况 Research Projects
五、代表性论文和专著 Representative papers
六、获奖情况